These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 26504027

  • 1. Effects of Vitamin K3 and K5 on Daunorubicin-resistant Human T Lymphoblastoid Leukemia Cells.
    Nakaoka E, Tanaka S, Onda K, Sugiyama K, Hirano T.
    Anticancer Res; 2015 Nov; 35(11):6041-8. PubMed ID: 26504027
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
    Liu ZL, Onda K, Tanaka S, Toma T, Hirano T, Oka K.
    Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
    [Abstract] [Full Text] [Related]

  • 4. Vitamins K2, K3 and K5 exert antitumor effects on established colorectal cancer in mice by inducing apoptotic death of tumor cells.
    Ogawa M, Nakai S, Deguchi A, Nonomura T, Masaki T, Uchida N, Yoshiji H, Kuriyama S.
    Int J Oncol; 2007 Aug; 31(2):323-31. PubMed ID: 17611688
    [Abstract] [Full Text] [Related]

  • 5. Persistent reversal of P-glycoprotein-mediated daunorubicin resistance by tetrandrine in multidrug-resistant human T lymphoblastoid leukemia MOLT-4 cells.
    Liu ZL, Hirano T, Tanaka S, Onda K, Oka K.
    J Pharm Pharmacol; 2003 Nov; 55(11):1531-7. PubMed ID: 14713364
    [Abstract] [Full Text] [Related]

  • 6. Cytotoxic effects of vitamins K1, K2, and K3 against human T lymphoblastoid leukemia cells through apoptosis induction and cell cycle arrest.
    Xu W, Wu H, Chen S, Wang X, Tanaka S, Sugiyama K, Yamada H, Hirano T.
    Chem Biol Drug Des; 2020 Oct; 96(4):1134-1147. PubMed ID: 32305047
    [Abstract] [Full Text] [Related]

  • 7. Effects of naturally occurring polymethyoxyflavonoids on cell growth, p-glycoprotein function, cell cycle, and apoptosis of daunorubicin-resistant T lymphoblastoid leukemia cells.
    Ishii K, Tanaka S, Kagami K, Henmi K, Toyoda H, Kaise T, Hirano T.
    Cancer Invest; 2010 Mar; 28(3):220-9. PubMed ID: 19863351
    [Abstract] [Full Text] [Related]

  • 8. Arsenic trioxide induces apoptosis in cells of MOLT-4 and its daunorubicin-resistant cell line via depletion of intracellular glutathione, disruption of mitochondrial membrane potential and activation of caspase-3.
    Hu XM, Hirano T, Oka K.
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):47-58. PubMed ID: 12750841
    [Abstract] [Full Text] [Related]

  • 9. Effects of vitamin K3 and K5 on proliferation, cytokine production, and regulatory T cell-frequency in human peripheral-blood mononuclear cells.
    Hatanaka H, Ishizawa H, Nakamura Y, Tadokoro H, Tanaka S, Onda K, Sugiyama K, Hirano T.
    Life Sci; 2014 Mar 18; 99(1-2):61-8. PubMed ID: 24503338
    [Abstract] [Full Text] [Related]

  • 10. Tetrandrine enhances glucocorticoid receptor translocation possibly via inhibition of P-glycoprotein in daunorubicin-resistant human T lymphoblastoid leukemia cells.
    Xu W, Wang X, Chen S, Wu H, Tanaka S, Onda K, Sugiyama K, Yamada H, Hirano T.
    Eur J Pharmacol; 2020 Aug 15; 881():173232. PubMed ID: 32525004
    [Abstract] [Full Text] [Related]

  • 11. Proteasome inhibitor bortezomib overcomes P-gp-mediated multidrug resistance in resistant leukemic cell lines.
    Zheng B, Zhou R, Gong Y, Yang X, Shan Q.
    Int J Lab Hematol; 2012 Jun 15; 34(3):237-47. PubMed ID: 22145750
    [Abstract] [Full Text] [Related]

  • 12. Vitamins K2, K3 and K5 exert in vivo antitumor effects on hepatocellular carcinoma by regulating the expression of G1 phase-related cell cycle molecules.
    Kuriyama S, Hitomi M, Yoshiji H, Nonomura T, Tsujimoto T, Mitoro A, Akahane T, Ogawa M, Nakai S, Deguchi A, Masaki T, Uchida N.
    Int J Oncol; 2005 Aug 15; 27(2):505-11. PubMed ID: 16010434
    [Abstract] [Full Text] [Related]

  • 13. Vitamins C and K3: A Powerful Redox System for Sensitizing Leukemia Lymphocytes to Everolimus and Barasertib.
    Ivanova D, Zhelev Z, Lazarova D, Getsov P, Bakalova R, Aoki I.
    Anticancer Res; 2018 Mar 15; 38(3):1407-1414. PubMed ID: 29491065
    [Abstract] [Full Text] [Related]

  • 14. In vitro induction of apoptosis and necrosis by new derivatives of daunorubicin.
    Stojak M, Mazur L, Opydo-Chanek M, Lukawska M, Oszczapowicz I.
    Anticancer Res; 2013 Oct 15; 33(10):4439-43. PubMed ID: 24123013
    [Abstract] [Full Text] [Related]

  • 15. Dexrazoxane has no impact on sensitivity of childhood leukemic blasts to daunorubicin.
    Styczynski J, Wysocki M, Balwierz W, Kowalczyk JR.
    Leukemia; 2002 May 15; 16(5):820-5. PubMed ID: 11986942
    [Abstract] [Full Text] [Related]

  • 16. [Effects of bortezomib combined with daunorubicin on proliferation and apoptosis in primary adult acute leukemia].
    Zhou RQ, Gong YP, Zheng BH, Yang X.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 Sep 15; 41(5):789-92. PubMed ID: 21302442
    [Abstract] [Full Text] [Related]

  • 17. Comparison of idarubicin and daunorubicin regarding intracellular uptake, induction of apoptosis, and resistance.
    Lotfi K, Zackrisson AL, Peterson C.
    Cancer Lett; 2002 Apr 25; 178(2):141-9. PubMed ID: 11867198
    [Abstract] [Full Text] [Related]

  • 18. Antitumor effects of vitamins K1, K2 and K3 on hepatocellular carcinoma in vitro and in vivo.
    Hitomi M, Yokoyama F, Kita Y, Nonomura T, Masaki T, Yoshiji H, Inoue H, Kinekawa F, Kurokohchi K, Uchida N, Watanabe S, Kuriyama S.
    Int J Oncol; 2005 Mar 25; 26(3):713-20. PubMed ID: 15703828
    [Abstract] [Full Text] [Related]

  • 19. Cell-cycle disturbance and induction of programmed death by new formamidine analogs of daunorubicin.
    Stojak M, Lukawska M, Oszczapowicz I, Opydo-Chanek M, Mazur L.
    Anticancer Res; 2014 Dec 25; 34(12):7151-8. PubMed ID: 25503143
    [Abstract] [Full Text] [Related]

  • 20. Vitamin K3 thio-derivative: a novel specific apoptotic inducer in the doxorubicin-sensitive and -resistant cancer cells.
    Hegazy MF, Fukaya M, Dawood M, Yan G, Klinger A, Fleischer E, Zaglool AW, Efferth T.
    Invest New Drugs; 2020 Jun 25; 38(3):650-661. PubMed ID: 31254176
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.